A Randomised Phase III Study of Trastuzumab-Docetaxel vs Trastuzumab-Vinorelbine as 1. Line Therapy for Patients With Metastatic HER2 Positive Breast Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Disease free survival
median
Michael Andersson, MD D Med Sci
Principal Investigator
Department of Oncology 5074, Rigshospitalet, 2100 Copenhagen, Denmark
Denmark: Danish Medicines Agency
HERNATA
NCT00430001
May 2005
December 2008
Name | Location |
---|